Antibodies to pituitary surface antigens during various pituitary disease states

Keda, Yulia; Krjukova, I V; Иловайская, И. А.; Morozova, M S; Фофанова, О. В.; Babarina, M B; Marova, Eugenia; Pankov, Y A; Кандрор, В. И.

doi:10.1677/joe.0.1750417

Cited by 16 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, Beressi and colleagues concluded their excellent review by writing "empty sella may in fact be the final term of initially undiagnosed lymphocytic hypophysitis". Pituitary antibodies have been found in patients with empty sella ( [27]; Mau found by IB antibodies against human GH and ACTH in 2 of 6 patients (33%) [28]; and Keda by ELISA found them in 16 of 38 patients (42%) [22]. On the other hand, Bensing and colleagues found no evidence of autoimmunity in patients with empty sella: antibodies to 49 kDa alpha-enolase were present in 6 of 30 patients (20%), similar to what found in healthy controls (11 of 50, 22%) [29].…”

Section: Pituitary Antibodies In Non-autoimmune Pituitary Diseasesmentioning

confidence: 99%

Pituitary autoimmunity: 30 years later

Caturegli

Lupi

Landek-Salgado

et al. 2008

Autoimmunity Reviews

158

147

View full text Add to dashboard Cite

Pituitary autoimmunity encompasses a spectrum of conditions ranging from histologically proven forms of lymphocytic hypophysitis to the presence of pituitary antibodies in apparently healthy subjects. Hypophysitis is a rare but increasingly recognized disorder that typically presents as a mass in the sella turcica. It mimics clinically and radiologically other non-secreting sellar masses, such as the more common pituitary adenoma. Hypophysitis shows a striking temporal association with pregnancy, and it has been recently described during immunotherapies that block CTLA-4. Several candidate pituitary autoantigens have been described in the last decade, although none has proven useful as a diagnostic tool. This review summarizes the advances made in the field since the publication of the first review on pituitary autoimmunity, and the challenges that await clarification.

show abstract

Section: Pituitary Antibodies In Non-autoimmune Pituitary Diseasesmentioning

confidence: 99%

Pituitary autoimmunity: 30 years later

Caturegli

Lupi

Landek-Salgado

et al. 2008

Autoimmunity Reviews

158

147

View full text Add to dashboard Cite

show abstract

“…Moreover, some patients with idiopathic hyperprolactinemia could have a probable silent LYH. In fact, Keda et al showed recently that autoantibodies to surface antigens of prolactin-secreting cells are revealed significantly more frequently in patients with idiopathic hyperprolactinemia than in cases of hyperprolactinemia due to adenoma [48]. This suggests that also the evaluation of APA in patients with apparently idiopathic hyperprolactinemia and inconclusive MRI could be useful to disclose cases of subclinical LYH.…”

Section: Hyperprolactinemia In Lyhmentioning

confidence: 99%

Prolactin and Autoimmunity

Bellis

Bizzarro

Pivonello³

et al. 2005

Pituitary

154

131

View full text Add to dashboard Cite

The interrelationship between prolactin (PRL) and the immune system have been elucitaded in the last decade, opening new important horizons in the field of the immunoendocrinology. PRL is secreted not only by anterior pituitary gland but also by many extrapituitary sites including the immune cells. The endocrine/paracrine PRL has been shown to stimulate the immune cells by binding to PRL receptors. Increased PRL levels, frequently described in autoimmune diseases, could depend on the enhancement of coordinated bi-directional communications between PRL and the immune system observed in these diseases. Hyperprolactinemia has been described in the active phase of some non organ-specific autoimmune diseases, as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and organ-specific autoimmune diseases, as celiac disease, type 1 diabetes mellitus, Addison's disease, autoimmune thyroid diseases. In these diseases PRL increases the syntesis of IFNgamma and IL-2 by Th1 lymphocytes. Moreover, PRL activates Th2 lymphocytes with autoantibody production. Of particular interest is the association between hyperprolactinemia and levels of anti DNA antibodies, islet cell antibodies (ICA), thyreoglobulin antibodies (TgAb), thyroperoxidase antibodies (TPOAb), adrenocortical antibodies (ACA), transglutaminase antibodies (tTGAb) in SLE, in type 1 diabetes mellitus, in Hashimoto's thyroiditis, in Addison's disease and in celiac disease, respectively. High levels of PRL have been also frequently detected in patients with lymphocytic hypophysitis (LYH). Several mechanisms have been invoked to explain the hyperprolactinemia in LYH. The PRL increase could be secondary to the inflammatory process of the pituitary gland but, on the other hand, this increase could have a role in enhancing the activity of the immune process in LYH. Moreover, the detection of antipituitary antibodies targeting PRL-secreting cells in some patients with idiopathic hyperprolactinemia suggests the occurrence of a possible silent LYH in these patients. Finally, the role of anti-prolactinemic drugs to inactivate the immune process in LYH is still discussed.

show abstract

“…Keda et al . showed that autoantibodies to surface antigens of PRL‐secreting cells are more frequently present in patients with idiopathic hyperprolactinemia than in cases of hyperprolactinemia due to adenoma 6 …”

Section: Introductionmentioning

confidence: 99%

Antipituitary Antibodies in Idiopathic Hyperprolactinemic Patients

Bellis

Colao

Pivonello

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Hyperprolactinemia is often observed in lymphocytic hypophysitis (LYH). To clarify the possible autoimmune pituitary involvement in patients with apparently idiopathic hyperprolactinemia we investigated the presence of antipituitary antibodies (APA) in hyperprolactinemic patients with idiopathic hyperprolactinemia and in those with prolactinoma. Sixty-six hyperprolactinemic patients (52 F, 14 M age range 28-42 years, group 1) were studied. Of them, 34 out of 66 showed clinical features of hyperprolactinemia and subsequently underwent cabergoline therapy; the 32 out of 66 patients without symptoms of hyperprolactinemia did not receive cabergoline therapy. Moreover, 32 patients (24 F/8M, age range 23-44 years) with hyperprolactinemia due to microprolactinoma (group 2) were also studied. APA, by immunofluorescence method, and anterior pituitary function were evaluated in both groups of patients. APA were present in 17 out of 66 (25.7%) patients in group 1 with titers ranging from 1/16 to 1/64. All patients of group 2 were considered APA negative because these antibodies were found at low titer (

show abstract

Antibodies to pituitary surface antigens during various pituitary disease states

Cited by 16 publications

References 22 publications

Pituitary autoimmunity: 30 years later

Pituitary autoimmunity: 30 years later

Prolactin and Autoimmunity

Antipituitary Antibodies in Idiopathic Hyperprolactinemic Patients

Contact Info

Product

Resources

About